Notably, there were strikingly up‐regulated TP63 levels in cancerous specimens of ESCC patients with advanced diseases (higher cancer grades, higher AJCC stages, or more lymph node metastases) compared with those of subjects with local diseases (lower cancer grades, lower AJCC stages, or less lymph node metastases) in TCGA (all P < 0.001) (Figure 3G–I). Here, TP63 is linked to metastatic malignant neoplasm in the lymph nodes.